Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Name: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
Published: 2019
License: Public Domain

Merck Sharp & Dohme LLC · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

advanced melanoma, programmed cell death 1 (pd-1, pd1), programmed cell death ligand 1 (pd-l1, pdl1), programmed cell death ligand 2 (pd-l2, pdl2), interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Related documents